hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06303284 id: Pending briefTitle: Post-surgical Outcomes With Anabolic Agent Use in High-risk Ankle Fractures: A Pilot RCT overallStatus: NOT_YET_RECRUITING date: 2025-01-01 date: 2026-12-31 date: 2027-06-01 date: 2024-03-12 date: 2024-03-18 name: University of Calgary class: OTHER briefSummary: As the global population ages and the prevalence of poor bone health increases among older patients with ankle fractures, so does the risk of post-surgical complications. Prevention of post-surgical complications is of paramount importance to reducing morbidity, mortality, and healthcare costs.
There is growing evidence to support the use of bone-building medications, such as Teriparatide, in patients who have delayed fracture healing or non-unions; however, these medications have yet to be investigated in elderly patients with ankle fractures at high risk for delayed fracture healing and post-operative complications. This project aims to assess the safety and efficacy of short-term Teriparatide use in improving outcomes in a population most likely to suffer post-operative complications.
The proposed study is a pilot randomized controlled trial (RCT) with patients 60 years or older with an additional risk factor for delayed healing (i.e., osteoporosis, diabetes, vascular disease) who require ankle fracture surgery. Participants will be randomized to receive the study medication (Teriparatide) or placebo for three months. The primary objective of this study is to acquire vital data (i.e., recruitment rates, follow-up rates, adherence to treatment assignment) required to determine the feasibility of a full-scale multi-centre RCT. Additional aims are to evaluate repeat surgery, complications, time-to-union, and 90-day mortality. A complete a socio-economic and feasibility analysis will be completed.
This study will evaluate the novel clinical approach of augmenting surgical fixation with a medication to build bone density and strength, thereby improving bone health, preventing complications, and improving outcomes. This study will also inform planning for a larger clinical trial to reduce the morbidity, mortality, and cost associated with complications in this high-risk population. conditions: Ankle Fractures studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: subcutaneous Teriparatide injection name: placebo measure: Participant recruitment rate measure: Incidence of composite measure of complications measure: Adverse events measure: modified Radiological Union Scale for Tibia [RUST] score), measure: Olerud Molander Score measure: EuroQol five dimensions [EQ-5D] measure: short form-12 [SF-12] measure: pain visual analogue score [VAS] measure: time-to-fracture union measure: 90 day mortality measure: Bone mineral density measure: Total cost and QALYs sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06303271 id: MUHAMMAD NISAR briefTitle: Transcutaneous Auricular Vagus Nerve Stimulation on Dizziness & Balance in Elderly Population overallStatus: RECRUITING date: 2024-02-01 date: 2024-06-30 date: 2024-06-30 date: 2024-03-12 date: 2024-03-12 name: Riphah International University class: OTHER briefSummary: The objective of the study is to determine the effects of transcutaneous auricular vagus nerve stimulation on dizziness and balance on elderly population with unilateral vestibular hypofunction. Patients will be divided into experimental and control group. Randomized participants will be allocated into control and experimental group. Intervention Group A received Vagus Nerve Stimulation (VNS) and Caw Thorne Cooksey exercise while Group group B received Caw Thorne Cooksey exercise only. Both groups received intervention of 30 minutes daily for 4 weeks (16 sessions). Assessment was done at the baseline, after 2 weeks and after 4 weeks conditions: Vestibular Hypofunction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 44 type: ESTIMATED name: Vagus Nerve Stimulation (VNS) and Caw Thorne Cooksey name: Caw Thorne Cooksey measure: The Dix-Hall pike test measure: Berg Balance Scale measure: The Dizziness Handicap Inventory (DHI) measure: Dynamic Gait Index (DGI) measure: Modified Clinical Test of sensory interaction & Balance (MCTSIB) sex: ALL minimumAge: 60 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ENT dept. of DHQ Mirpur AJK status: RECRUITING city: Kashmir country: Pakistan name: Nadia Azhar, NMPT role: CONTACT phone: 03335281431 email: nadia.azhar@riphah.edu.pk hasResults: False
nctId: NCT06303258 id: RiphahIU Sharmeen Kanwar briefTitle: Generalized Versus Core Stabilization Antenatal Exercises For Lumbopelvic Pain overallStatus: RECRUITING date: 2024-03-04 date: 2024-05-01 date: 2024-06-30 date: 2024-03-12 date: 2024-03-12 name: Riphah International University class: OTHER briefSummary: Core stability training has gained popularity as a fitness trend and is now being used in rehabilitation programs as well the patient adherence to this intervention has been low due to its complex nature, particularly pregnant females .Limited literature is available to present the effect of core stabilization exercises in comparison to the other handful simplified techniques and exercises This study compares two interventions for this particular condition to identify a feasible and enjoyable therapeutic intervention for the pregnant women who suffer Lumbopelvic Pain. conditions: Low Back Pain conditions: Pelvic Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Single (Outcomes Assessor) whoMasked: OUTCOMES_ASSESSOR count: 48 type: ESTIMATED name: Core Stabalization Exercises name: Generalized Antenatal Exercises measure: Visual Analogue Scale (VAS) measure: Visual Analogue Scale (VAS) measure: Pregnant women's quality of life questionnaire (QOL-GRAV) measure: Pregnant women's quality of life questionnaire (QOL-GRAV) sex: FEMALE minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: Tehsil Headquarter Hospital Raiwind status: RECRUITING city: Lahore state: Punjab zip: 55150 country: Pakistan name: Sharmeen Kanwar, MS-WHPT* role: CONTACT phone: 0307-8778164 email: kanwarsharmeen@gmail.com lat: 31.558 lon: 74.35071 hasResults: False
nctId: NCT06303245 id: REC/RCR&AHS/23/0579 briefTitle: Effects of Abdominal Binders and TENS on Puerperium Period After Cesarean Section overallStatus: RECRUITING date: 2023-02-23 date: 2024-08-01 date: 2024-09-01 date: 2024-03-12 date: 2024-03-12 name: Riphah International University class: OTHER briefSummary: To determine the combined effects of abdominal binders and TENS on post-operative pain, distress and constipation in puerperium period after cesarean section conditions: Cesarean Section; Complications, Wound, Dehiscence studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 28 type: ESTIMATED name: ABDOMINAL BINDERS name: TENS measure: o Numeric Pain rating Scale measure: o Symptom Distress scale measure: o PAC-SYM Questionnaire sex: FEMALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: PAF hospital status: RECRUITING city: Lahore zip: 05499 country: Pakistan name: imran amjad role: CONTACT phone: 03324390125 email: imran.amjad@riphah.edu.pk name: Mishal Jamal, MSPT(WH) role: PRINCIPAL_INVESTIGATOR lat: 31.558 lon: 74.35071 hasResults: False
nctId: NCT06303232 id: REC/RCR&AHS/23/0578 briefTitle: Effects of Manual Lymphatic Drainage and Therapeutic Ultrasound on Breast Engorgement overallStatus: RECRUITING date: 2023-02-23 date: 2024-08-01 date: 2024-09-01 date: 2024-03-12 date: 2024-03-12 name: Riphah International University class: OTHER briefSummary: To find the combined effects of the manual lymphatic drainage with therapeutic ultrasound on breast engorgement, pain and self-efficacy in post - partum women. conditions: Postpartum Complication studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 42 type: ESTIMATED name: MANUAL LYMPHATIC DRAINAGE name: THERAPEUTIC ULTRASOUND measure: Visual Analogue Scale - VAS measure: Six Point Engorgement Scale - SPE measure: Breastfeeding Self-Efficacy Scale - BSES sex: FEMALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Innovative Health Concepts Clinic status: RECRUITING city: Lahore zip: 05499 country: Pakistan name: hina gul gul role: CONTACT phone: 03214979172 email: hina.gul@riphah.edu.pk name: Irsa Zahid, MSPT(WH) role: PRINCIPAL_INVESTIGATOR lat: 31.558 lon: 74.35071 hasResults: False
nctId: NCT06303219 id: REC/RCR&AHS/23/0577 briefTitle: Effects of Traditional Moderate Intensity Training and High Intensity Interval Training in Polycystic Ovarian Syndrome overallStatus: RECRUITING date: 2023-11-23 date: 2024-08-01 date: 2024-09-01 date: 2024-03-12 date: 2024-03-12 name: Riphah International University class: OTHER briefSummary: To determine the comparative effects of traditional moderate intensity training and high intensity interval training on Anxiety, fatigue and Quality of Life in females with polycystic ovarian syndrome conditions: Polycystic Ovarian Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 44 type: ESTIMATED name: RADITIONAL MODERATE INTENSITY TRAINING name: HIGH INTENSITY INTERVAL TRAINING measure: Hamilton Anxiety Rating scale (HAM-A) measure: The Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ) measure: The Fatigue Impact Scale (FIS) sex: FEMALE minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Gynecological Department of Fatima Memorial Hospital status: RECRUITING city: Lahore zip: 05499 country: Pakistan name: hina gul gul role: CONTACT phone: 03214979172 email: hina.gul@riphah.edu.pk name: Fatima Kashif, MSPT(WH) role: PRINCIPAL_INVESTIGATOR lat: 31.558 lon: 74.35071 hasResults: False
nctId: NCT06303206 id: H23-00623 briefTitle: TEC4Home Blood Pressure Randomized Controlled Trial overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2027-01-01 date: 2027-01-01 date: 2024-03-12 date: 2024-03-12 name: University of British Columbia class: OTHER briefSummary: The goal of this clinical trial is to evaluate the effect of home blood pressure telemonitoring (HBPT) and case management (CM), relative to usual care, for improving blood pressure (BP) control among patients with high blood pressure discharged from the emergency department (ED).
Participants in the intervention group will receive training and use of a home BP telemonitor with tele-transmission function for 12-months plus pharmacist case management to provide behavioral counseling, facilitate medication adherence, review telemonitored BP data, and adjust medications. The control group will receive usual care from their primary care physician and will receive the same home BP monitor and hypertension education. conditions: Hypertension studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 408 type: ESTIMATED name: Home Blood Pressure Telemonitoring (HBPT) + Case Management (CM) measure: Systolic blood pressure controlled measure: Impact of intervention on other blood pressure measures sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06303193 id: 10001554 id: 001554-C briefTitle: Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2030-01-01 date: 2035-01-01 date: 2024-03-12 date: 2024-04-26 name: National Cancer Institute (NCI) class: NIH briefSummary: Background:
Bone marrow biopsies, heart tests, and other tests will be repeated at intervals throughout the study. Participants will also fill out questionnaires about their quality of life, the symptoms of their disease, and other topics. conditions: Myelodysplastic Syndromes studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 160 type: ESTIMATED name: pacritinib measure: Recommended phase 2 dose of pacritinib in participants 12-17 years of age measure: Efficacy as measured by Objective Response Rate (ORR) per each risk-based cohort measure: Pharmacokinetic (PK) properties of pacritinib measure: Extended safety of pacritinib sex: ALL minimumAge: 12 Years maximumAge: 120 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: National Institutes of Health Clinical Center city: Bethesda state: Maryland zip: 20892 country: United States name: National Cancer Institute Referral Office role: CONTACT phone: 888-624-1937 email: NCIMO_Referrals@mail.nih.gov lat: 38.98067 lon: -77.10026 hasResults: False
nctId: NCT06303180 id: 10001560 id: 001560-DC briefTitle: NIDCD Otolaryngology Clinical Protocol Biospecimen Bank overallStatus: RECRUITING date: 2024-03-04 date: 2033-12-30 date: 2033-12-30 date: 2024-03-12 date: 2024-04-02 name: National Institute on Deafness and Other Communication Disorders (NIDCD) class: NIH briefSummary: Background:
Samples may be used for genetic testing. conditions: Hearing Loss conditions: Head and Neck Neoplasms conditions: Hearing Disorders conditions: Laryngeal Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED measure: To create a biorepository of diseased and normal tissue specimens for research purposes. measure: To share specimens with the NCI Frederick Patient-Derived Xenograft (PDX) team, other approved protocols or may be used under this protocol to conduct analysis of cellular, molecular, genetic and genomic biology of sex: ALL minimumAge: 3 Years maximumAge: 99 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: National Institutes of Health Clinical Center status: RECRUITING city: Bethesda state: Maryland zip: 20892 country: United States name: Marcia Mulquin, RN, MSN role: CONTACT phone: 301-496-1601 email: mmulquin@mail.nih.gov name: NIH Clinical Center Office of Patient Recruitment (OPR) role: CONTACT phone: (800) 411-1222 phoneExt: TTY dial 711 email: ccopr@nih.gov lat: 38.98067 lon: -77.10026 hasResults: False
nctId: NCT06303167 id: NCI-2024-01150 id: NCI-2024-01150 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: EAY131-E type: OTHER domain: ECOG-ACRIN Cancer Research Group id: EAY131-E type: OTHER domain: CTEP id: U10CA180820 type: NIH link: https://reporter.nih.gov/quickSearch/U10CA180820 briefTitle: Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) overallStatus: ACTIVE_NOT_RECRUITING date: 2015-08-06 date: 2024-05-26 date: 2024-05-26 date: 2024-03-12 date: 2024-03-12 name: National Cancer Institute (NCI) class: NIH briefSummary: This phase II MATCH treatment trial evaluates the effectiveness of osimertinib (AZD9291) in treating patients with cancer that has certain genetic changes called EGFR mutations. Osimertinib is in a class of medications called kinase inhibitors. It works by blocking the action of mutant forms of the EGFR protein, which play a key role in tumor cell growth. Osimertinib may cause tumor cell death and inhibit tumor growth in EGFR-overexpressing tumor cells, thereby stopping or slowing the spread of tumor cells. conditions: Advanced Lymphoma conditions: Advanced Malignant Solid Neoplasm conditions: Hematopoietic and Lymphoid Cell Neoplasm conditions: Refractory Lymphoma conditions: Refractory Malignant Solid Neoplasm conditions: Refractory Multiple Myeloma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: Biopsy name: Biospecimen Collection name: Echocardiography name: Multigated Acquisition Scan name: Osimertinib name: Radiologic Examination measure: Objective response rate measure: Overall survival measure: Progression free survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06303154 id: EC45 MOBIBRA id: ID-RCB type: OTHER domain: 2023-A01937-38 briefTitle: Evaluation of Mobiderm Intimate Bra in the Management of Breast Edema Related to Breast Cancer Treatment acronym: MOBIBRA overallStatus: RECRUITING date: 2024-03-21 date: 2025-09 date: 2025-09 date: 2024-03-12 date: 2024-04-16 name: Thuasne class: INDUSTRY briefSummary: The aim of this exploratory study is to assess the performance and tolerability of the MOBIDERM Intimate Bra in the management of breast edema related to breast cancer treatment. conditions: Breast Cancer Surgery studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective, exploratory, monocentric, uncontrolled clinical study. primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Mobiderm Intimate Bra group measure: Evolution of breast edema severity measure: Comparison of methods to follow changes in the severity of breast edema - TDC measurement measure: Comparison of methods to follow changes in the severity of breast edema - Clinical assessment measure: Comparison of methods to follow changes in the severity of breast edema - Ultrasound measurement measure: Time to edema onset measure: Time to edema disappearance measure: Symptoms and quality of life changes associated with breast edema measure: Breast edema hypersensitivity measure: Breast pain measure: Skin changes associated with breast edema measure: Physical activity measure: Healing time measure: Safety of the device measure: Compliance to the device measure: Patient's satisfaction sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Groupe Hospitalier Paris Saint Joseph - Groupement FEHAP status: RECRUITING city: Paris state: Paris 14 zip: 75014 country: France name: Séverine ALRAN, Dr role: CONTACT lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06303141 id: LUC/CPGS/PGS/20230405/001 briefTitle: Comparative Effects of Neuromuscular Training and Mobilization With Movement in Professional Athletes With Ankle Sprain overallStatus: COMPLETED date: 2023-04-05 date: 2023-09-05 date: 2023-09-10 date: 2024-03-12 date: 2024-03-12 name: Riphah International University class: OTHER briefSummary: The study aims to compare the effects of neuromuscular training and mobilization with movement on pain, range of motion, function, and disability in professional athletes with ankle sprain. Neuromuscular training focuses on improving neuromuscular control and stability, while mobilization with movement aims to restore joint mobility and function. By investigating the outcomes of these two interventions, the study seeks to provide insights into their effectiveness for managing ankle sprains in professional athletes. conditions: Ankle Injuries conditions: Musculoskeletal Manipulations studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: the assessor who take the reading is blind whoMasked: OUTCOMES_ASSESSOR count: 60 type: ACTUAL name: Closed Chain exercises name: Neuromuscular Training name: Mobilization with Movement measure: Numerical Pain Rating Scale for Pain measure: Goniometer for Range of Motion measure: Star balance excursion test for Balance measure: Foot and ankle ability Measure for Functional Performance measure: Cumberland Ankle Instability measure: Agility T-test measure: Speed (20m sprint test) sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: Pakistan Sports Board city: Lahore state: Punjab country: Pakistan lat: 31.558 lon: 74.35071 hasResults: False
nctId: NCT06303128 id: IRB-FY2024-61 briefTitle: Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge overallStatus: RECRUITING date: 2024-02-03 date: 2024-12 date: 2025-05 date: 2024-03-12 date: 2024-03-15 name: James Tarbox, MD class: OTHER name: Texas Tech University Health Sciences Center briefSummary: The goal of this clinical trial is to learn about dosing when testing to see if a penicillin allergy label can be removed from adults that had been labeled as "penicillin-allergic" previously. The main question it aims to answer is:
Participants will, after being identified as having a low-risk penicillin allergy, be administered oral amoxicillin in a controlled setting and then monitored for an allergic reaction. Researchers will compare participants that took one dose of amoxicillin to participants that took two doses of amoxicillin (a small dose and then a larger dose) to see if either group was more likely to develop an allergic reaction. conditions: Penicillin Allergy studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: - Low-risk penicillin allergic patients ("low-risk" determined by a PEN-FAST score of 2 or less) will be recruited. Clinically stable patients will be randomly assigned in a double-blinded manner to receive either a one-dose or graded two-dose direct oral challenge with amoxicillin in an outpatient setting. Those assigned to receive one dose of amoxicillin will receive a placebo in place of a second dose of amoxicillin. Both groups will receive the same cumulative dose of amoxicillin (250mg) by the end of the trial. Baseline vital signs will be obtained and tracked throughout the trial. Patients will also be monitored for development of signs of allergic reactions during the trial, with administration of appropriate treatment should the need arise. primaryPurpose: DIAGNOSTIC masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 380 type: ESTIMATED name: Amoxicillin 250 MG name: Placebo name: Amoxicillin 62.5mg name: Amoxicillin 187.5mg measure: Proportion of successfully "delabeled" subjects in one-dose versus two-dose groups measure: Analysis of adverse reactions measure: Analysis of medical and allergic history measure: Validation of penicillin allergy delabeling measure: Analysis of demographic data sex: ALL minimumAge: 18 Years maximumAge: 89 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Texas Tech University Health Sciences Center status: RECRUITING city: Lubbock state: Texas zip: 79430 country: United States name: Study Coordinator role: CONTACT phone: 806-543-8994 email: clinicalresearch@ttuhsc.edu name: Joshua A Peterson, MD role: CONTACT email: josh.peterson@ttuhsc.edu name: Joshua A Peterson, MD role: SUB_INVESTIGATOR name: Nicole Welch, MD role: SUB_INVESTIGATOR name: KaKa L Adams, MD role: SUB_INVESTIGATOR name: Barbara Mora Gonzalez, MD role: SUB_INVESTIGATOR name: Sebastian Sanchez Lopez, MD role: SUB_INVESTIGATOR name: Sierra Sullivan, MD role: SUB_INVESTIGATOR name: Jacob Nichols, MD role: PRINCIPAL_INVESTIGATOR name: James A Tarbox, MD role: PRINCIPAL_INVESTIGATOR lat: 33.57786 lon: -101.85517 hasResults: False